Key result
Empagliflozin significantly improved endothelial function, with median flow-mediated dilatation increasing from 3.5% to 4.7%, in diabetic patients with coronary artery disease.
Why the study?
The mechanisms underlying the cardiovascular benefits of SGLT2 inhibitors have not been fully clarified.
Does empagliflozin 10 mg/d improve endothelial function and metabolic parameters in diabetic patients with coronary artery disease?
Observational (n=50)
Open-label
No
Does empagliflozin 10 mg/d improve endothelial function and metabolic parameters in diabetic patients with coronary artery disease?
Empagliflozin improves endothelial function in diabetic patients with CAD, a benefit that appears strongly associated with reductions in plasma triglycerides.
Answers are grounded in this paper and cite their sources.
TG reduction may link empagliflozin to endothelial recovery in diabetic CAD; leaves open causal role in CV outcomes.
AIM: So far, the mechanisms behind the cardiovascular benefits of sodium/glucose cotransporter 2 (SGLT2) inhibitors have not been fully clarified. METHODS: In order to evaluate the effects of SGLT2 inhibitors on systemic hemodynamics, glucose metabolism, lipid profile, and endothelial function, 50 diabetic patients with established coronary artery disease (CAD) were included in this analysis and were given empagliflozin 10 mg/d. Cookie meal testing (carbohydrates: 75 g, fats: 28.5 g), endothelial function testing using flow-mediated dilatation (FMD), and body composition evaluation were performed before and after six months of treatment. Changes in %FMD between the treatment periods and its association with metabolic biomarkers were evaluated. RESULTS: After six months of treatment, the body weight and body fat percentage decreased significantly, while the body muscle percentage increased significantly. The hemoglobin A1c level and fasting and postprandial plasma glucose levels were significantly decreased with treatment. Postprandial insulin secretion was also significantly suppressed and the insulin resistance index was significantly decreased. Furthermore, the fasting and postprandial triglyceride (TG) levels decreased significantly, while total ketone bodies increased significantly after the six-month treatment. While the plasma brain natriuretic peptide level was not changed, the C-reactive protein level was decreased and FMD was significantly improved after the six-month treatment. Multiple regression analysis showed that the strongest predictive factor of FMD improvement is change in the plasma TG levels. CONCLUSION: SGLT2 inhibitors improve multiple metabolic parameters. Of these, a reduction in plasma TGs was strongly associated with endothelial function recovery in diabetic patients with CAD, and this reduction may be related to the cardiovascular benefits of SGLT2 inhibitors.
No takes yet. Share an insight, caveat, or question.
Sawada et al. (2019) conducted an observational in Type 2 diabetes mellitus with coronary artery disease (n=50). Empagliflozin vs. Baseline (single-arm) was evaluated on Change in % flow-mediated dilatation (%FMD) (p=0.001). Empagliflozin significantly improved endothelial function, with median flow-mediated dilatation increasing from 3.5% to 4.7%, in diabetic patients with coronary artery disease.
Synapse has enriched 10 related papers. Consider them for comparative context: